Replies to post #6902 on GTC Biotherapeutics (fka GTCB)

[biopearl]

And we're talking ORAL replacement therapy not just IV. bp

[DewDiligence]

>…Hemophilia A or Factor VIII deficiency is much more common than Hemophilia B or Factor IX deficiency so I find it interesting that GTCB decided not to collaborate with LFB on Factor VIII.<

They could still do so later. FIX may be a more attractive opportunity than FVIII in acute-care settings.